|
|
To make sure their existing solutions and strategies are able to accommodate the needs of customers and their therapies, Lonza recently conducted a survey to confirm the challenges in upstream, downstream, and analytical development of new molecular formats, as well as identify any additional challenges in developing biologics based on them.
|